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ABSTRACT 
 
Anti-inflammatory drugs (both COX-2 inhibitors 
and nonselective non-steroidal anti-inflammatory 
drugs = NSAIDs), paracetamol and opioid agents 
are associated with potentially different adverse 
events with varying degrees of efficacy. The present 
work was conducted to elucidate the haemato-
immunological changes in mice when treated with 
diclofenac (Diclo), ibuprofen (Ibu) and paracetamol 
(Para). Mice were intraperitoneally administered 
with Diclo (7.4 mg/kg and 14.8 mg/kg), Ibu (60 
mg/kg and 120 mg/kg) or Para (36.7 mg/kg and 73.4 
mg/kg) daily for one month against saline-treated 
mice served as control. Diclo administration (14.8 
mg/kg) caused decrease in RBCs count, Hb content 
and Hct%, depending on dose toxicity, while 
paracetamol and ibuprofen treatment showed 
increase in RBCs count, Hb content and Hct%. 
Additionally, all tested drugs induced activities of 
IgM and C-reactive protein in serum and caused 
perturbations in absolute and relative weight of 
immune related organs. Further, Diclo and Para 
treatments reduced levels of IgG in dose dependent 
manner however, Ibu administration enhanced 
activities of IgG that was reduced with increasing 
dose of Ibu. And activities of serum complement 
component C3 was diminished after administration 
of tested drugs activating alternative complement 
pathway. The implication of this research is that 
long use of diclofenac, ibuprofen or paracetamol 
may cause immunotoxic and hematotoxic effects in 
mice; and the dose plus the duration of treatment 
may augment their toxicity probably due to immune 
modulatory effects. Further studies are needed to 
assess the relevance between Diclo, Ibu or Para 
treatment and immunological and hematological 
perturbations.  
                                                                                                         
Keywords: Immunological and hematological 
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1. INTRODUCTION 
 
 The main analgesic agents that generally used 
for the most popular types of pain, include non-
steroidal anti-inflammatory drugs (NSAIDs; both 
traditional non-selective and cyclo-oxygenase 
(COX)-2 selective agents), paracetamol and opioids 
[1]. NSAIDs have exhibited excellent efficacy in  
the control of acute pain producing both anti-
inflammatory and analgesic effects [2, 3] by inhibi-
tion of prostaglandin synthesis via the COX enzyme 
that regulates normal physiological turnover of 
prostaglandin and maintains integrity of gastric 
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lining and renal homeostasis [4]. The therapeutic 
anti-inflammatory action of NSAIDs is produced                
by the inhibition of COX-2, while the potential 
damaging pernicious effects emerge from inhibition 
of physiological COX-1 activity [5]. 
 Traditional NSAIDs such as ibuprofen or 
diclofenac, have been established to inhibit COX 
enzyme activity [6] resulting in the prevention of 
synthesis of prostaglandins that interfere pivotal 
physiological functions, including gastric cytopro-
tection, maintenance of renal blood flow, and 
platelet activation [7]. Ibuprofen (Ibu), an over-the-
counter (OTC) drug, is one of the most widespread 
used NSAIDs as an analgesic, antipyretic, and anti-
inflammatory drug globally [8, 9]. Although, 
NSAIDs are commonly considered to have high 
safety profiles, the frequent and general use of 
ibuprofen and other NSAIDs is likely to increase the 
prevalence of their adverse effects. Ibuprofen and 
other NSAIDs are commonly linked to gastro-
intestinal (GI) toxicity [10, 11] and alternation in 
renal function [12, 13]. So, regular toxicological 
evaluation of NSAIDs becomes essential. 
 Diclofenac (Diclo) is a widely circulated 
drug, used in humans and animals for the treatment 
and management of inflammation, fever and pain 
associated with disease or injury of domestic 
livestock and humans, regarding to its anti-
inflammatory, analgesic and antipyretic properties, 
however it has severe pathologic conditions such as 
peptic ulceration, gastrointestinal bleeding, hepato-
toxicity, renal papillary necrosis and renal failure on 
long-term of the drug administration [14-16]. Anti-
inflammatory, antipyretic and analgesic action of 
Diclo is related to inhibition of prostaglandin 
synthesis from arachidonic acid by inhibition of 
cyclooxygenase (COX) [17]. Diclofenac was found 
to cause pathological changes in kidneys of the 
vultures leading eventually to the gout [18] and a 
rare but potentially fetal hepatotoxicity that may be 
related to reactive metabolites formation [19-21].   
 Alternative to NSAIDs, paracetamol (Para) is 
one of the most popular drugs around the world, 
available without a prescription, especially in child-
hood [22, 23]. Similar to NSAIDs, Para has a potent 
antipyretic and analgesic actions but without anti-
inflammatory activity and a weak inhibition of 
prostaglandins synthesis [24, 25]. Also, it has a 
spectrum of action analogous to that of NSAIDs and 
mostly resembles the COX-2 selective inhibitors. In 
spite of its wide use, the mechanism of action of 
acetaminophen has not been fully elucidated, but          
it is commonly agreed that it inhibits COX-1             
and COX-2 through metabolism by the peroxidase 
function of these isoenzymes, the possibility exists 
that  it inhibits a so far unidentified form of COX, 
perhaps COX-3 [26] or there is another mechanism 
of action that include the effects of both the 
peripheral (inhibition of COX activity) and central 
(COX, descending serotoninergic pathways, L-argi-
nine/NO pathway, cannabinoid system) antinoci-
ceptive processes as well as the redox mechanism 
[27] concluding that Para has a multifactorial 
mechanism of action, which may include the 
activation of different pain pathways hence the 
difficulty in clarifying the delicate mechanism of 
action [28]. Although Para is safe and well tolerated 
when taken in the usual therapeutic dose, its 
overdose is fairly common and often linked with 
hepatic and renal damage in both humans and 
experimental animals [29, 30].  
 Due to dearth of information from literature 
on the adverse effects of Diclofenac sodium, 
Ibuprofen and Paracetamol on immunological and 
hematological parameters in mice, therefore the 
present study was planned with the objective to 
investigate the immunomodulatory and hematolo-
gical effects of repeated doses of diclofenac, 
ibuprofen or paracetamol in mice for one month.  
 
2. MATERIALS AND METHODS 
 
2.1. Experimental animals 
 
 Male Swiss albino mice were obtained from 
Company for Biological Products and Vaccines 
(VACSERA), Cairo, Egypt. Animals were 4-6 
weeks old and weighed between 20-28 g at the 
beginning of the experiment. They were handled and 
kept in a specific pathogen-free facility at Faculty of 
Science, Tanta University in accordance with the 
ethical guidelines of Egyptian National Research 
Center, Cairo, Egypt and has therefore been 
performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and 
its later amendments. All animals were housed 
under the same environmental conditions for 1 week 
before experimentation for acclimatization and to 
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ensure normal growth and behavior. The mice          
were housed under standard laboratory conditions 
(temperature 22°C ± 2°C; 12 h light-dark cycle) and 
kept in plastic cages with free access to the 
commercial basal food and water.  
 
2.2. Drugs 
 
 The tested drugs: diclofenac sodium (Diclo) 
(each tablet contains 50 mg diclofenac sodium, 
Novartis Pharma, Cairo, Egypt), ibuprofen (Ibu) 
(each tablet contains 200 mg ibuprofen, Kahira 
Pharaceuticals & Chemical Industries Company, 
Cairo, Egypt), and paracetamol (Para) (each tablet 
contains 500 mg of active drug, Arab Drug Com-
pany, Cairo, Egypt) were purchased from public 
drug store (Tanta, Egypt). Each tablet was crushed 
to fine powder and dissolved in saline at appropriate 
concentrations.  
 
2.3. Experimental design 
 
 Mice were divided into seven groups of             
ten animals each. Group1 was administrated saline 
(i.p.) as a control group, group 2 and group 3, i.p. 
inoculated with Diclo (14.8 mg/kg, 5 time less         
than LD50 and 7.4 mg/kg, 10 time less than LD50 
respectively [31], group 4 and group 5, i.p. injected 
with Ibu (120 mg/kg, 5 time less than LD50 and 60 
mg/kg, 10 time less than LD50 correspondingly 
[32], group 6 and group 7, i.p. injected with Para 
(73.4 mg/kg, 5 time less than LD50 and 36.7 mg/kg, 
10 time less than LD50 separately) [33] daily for a 
period of one month. At the end of treatment,         
three mice from each group were euthanized by 
cervical dislocation at fasting state. Preceding to the 
scarifying, blood samples were collected from retro-
orbital plexus for immunological and hematological 
analyses.  
 
2.4. Hematological analysis  
 
 Blood parameters were proceeded for hemato-
logical analysis using a Nihon Kohden automated 
hematology analyzer (model MEK-6318K, Japan), 
including red blood cell count (RBC) (106/µl), 
hemoglobin concentrations (Hb g/dl), hematocrit 
percentage (Hct%) and platelet count (Plt) (103/µl).  
 
2.5. Preparation of sera samples 
 
 At the end of experiment, three mice from 
each group were euthanized by cervical dislocation 
at fasting state. Prior to a euthanizing, blood samples 
were collected from retro-orbital plexus in plastic 
test tubes and allowed to stand for 3 h to ensure 
complete clotting. The clotted blood samples were 
centrifuged at 3000 rpm for 10 min and the clear 
sera samples were aspirated off and stored frozen at 
˗80°C for immunological analyses. Evaluation of the 
different immunological parameters: Complement 
component C3, C4 and C-reactive protein (CRP). 
Serum levels of IgG and IgM in exposed mice were 
performed using enzyme linked immuno-sorbent 
assay (ELISA) as described by [34, 35] in triplicate 
for each sample. The manufacturer's instructions for 
each parameter were strictly followed in the course 
of the investigations.  
 
2.6. Body weight gain and immune-related 
organs relative weight  
 
 Just before killing after 30 days, final body 
weight of mice in all experimental groups was 
recorded. Upon being killed, the spleen, lymph 
nodes and thymus were removed aseptically, 
weighed and their relative organ weights (ROW) 
were calculated according to Aniagu et al. [36] using 
the following formula:  
ROW = [Absolute organ weight (g) / body weight of 
mice on sacrifice day (g)] × 100.  
 Percentage weight gains of mice (WG%) were 
calculated according to Tukmechi et al. [37] using 
the following formula: WG% = (final body weight - 
initial body weight) × 100/initial body weight).  
 
2.7. Statistical analysis 
 
 The data were expressed as mean ± standard 
error of the mean (n = 3). Statistical comparisons 
among prospective groups were analyzed using a 
one-way analysis of variance (ANOVA) as part of 
an SPSS software package (v.16.0 for Windows, 
2007; SPSS, Inc., Chicago, IL). Statistical signifi-
cance was determined by a post hoc test followed  
by Dunnett’s multiple comparison tests to com-  
pare treatment means versus respective controls. 
Significant differences are indicated as follows:     
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*, P < 0.05; **, P < 0.01 for significant and highly 
significant differences, respectively. 
 
3. RESULTS 
 
 The current study was conducted to investi-
gate the adverse effects of daily administration of 
different pain killers like Diclofenac sodium (Diclo), 
Ibuprofen (Ibu) and Paracetamol (Para) intraperi-
toneally for one month on immunological and 
hematological changes in mice. The present findings 
indicated that 1-month continuous treatment with 
Diclo, Ibu and Para has altered the immuno-
hematological parameters in the processed mice. 
 The adverse effects of Diclo, Ibu and Para 
administration on body weight gain, absolute and 
relative weight of liver and kidney in the albino 
mice are indicated in Table 1. The obtained data 
revealed non-significant decrease in the monitored 
weight gain in all treatments used in this study, 
when compared to saline treated group. Further, 
absolute and relative weight of liver and kidney 
showed non-significant changes comparing to 
saline-treated mice.  
 
 
Table 1. Changes in body weight, percentage of body weight gain, absolute and relative weight of liver and kidney after 
treatment with Diclo, Ibu or Para.
 
    
Treatment 
Body wt Liver Kidney 
Initial 
Body WT 
Final 
Body WT 
Body WT 
gain (%) 
Absolute 
WT 
Relative 
WT 
Absolute 
WT 
Relative 
WT 
Control 23.47±2.39 30.11±3.12 28.29±3.79 1.68±0.17 5.63±0.58 0.5±0.06 1.64±0.05 
Diclo (7.4 mg/kg) 22.00±0.61 28.47±0.81 29.44±2.61 1.89±0.16 6.33±0.26 0.45±0.02 1.51±0.01 
Diclo (14 mg/kg) 20.80±0.12 25.40±0.81 22.10±3.58 1.42±0.10 5.92±0.18 0.38±0.01 1.59±0.15 
Ibu (60 mg/kg) 23.23±0.66 28.37±0.55 22.21±2.75 1.40±0.08 5.36±0.21 0.45±0.05 1.73±0.14 
Ibu (120 mg/kg) 24.33±1.79 29.23±0.75 21.01±5.93 1.57±0.14 5.35±0.34 0.4±0.02 1.36±0.03 
Para (36.7 mg/kg) 23.80±0.81 29.51±0.7 24.42±6.73 1.71±0.08 5.79±0.24 0.41±0.01 1.40±0.02 
Para (73.4 mg/kg) 24.47±2.09 30.67±2.37 26.07±7.71 1.61±0.21 5.22±0.44 0.46±0.03 1.49±0.02 
Data were represented as mean ± SE (n = 3). *: Statistically significant comparison of control group and other treated 
groups (p < 0.05), **: Highly significant (p < 0.01). 
 
 
Table 2. Changes in absolute and relative weight of spleen, thymus and lymph node of mice after treatment with Diclo, Ibu 
or Para.
 
 
 
Treatment 
Spleen Thymus Lymph node 
Absolute WT Relative WT Absolute WT 
Relative 
WT Absolute WT 
Relative 
WT 
Control 0.22±0.04 0.72±0.06 0.05±0.01 0.17±0.02 0.08±0.003 0.26±0.02 
Diclo (7.4 mg/kg) 0.27±0.05 0.89±0.14 0.07±0.01 0.25±0.03 0.08±0.003 0.28±0.01 
Diclo (14 mg/kg) 0.28±0.05 1.15±0.14** 0.04±0.01 0.17±0.03 0.06±0.006 0.25±0.02 
Ibu (60 mg/kg) 0.14±0.02* 0.53±0.09* 0.04±0.01 0.15±0.02 0.06±0.010 0.24±0.04 
Ibu (120 mg/kg) 0.13±0.02** 0.43±0.06** 0.04±0.00 0.15±0.01 0.05±0.006 0.17±0.02 
Para (36.7 mg/kg) 0.17±0.01 0.57±0.03 0.03±0.00 0.11±0.01 0.04±0.006* 0.14±0.02* 
Para (73.4 mg/kg) 0.16±0.05* 0.51±0.13* 0.07±0.02 0.22±0.06 0.05±0.010* 0.15±0.04* 
Data were represented as mean ± SE (n = 3). *: Statistically significant comparison of control group and other treated 
groups (p < 0.05), **: Highly significant (p < 0.01). 
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 The relative and absolute weights of immune 
organs (spleen, thymus and lymph node) in albino 
mice are illustrated in Table 2. 
The present finding showed that Diclo (7.4 
mg/kg and 14.8 mg/kg) treatments resulted in signi-
ficant increase in spleen relative weight, whereas 
there was significant decrease with Ibu (60 mg/kg 
and 120 mg/kg) and Para (73.4 mg/kg) admini-
stration and non-significant decrease with Para (36.7 
mg/kg) treatment compared to saline-treated mice. 
Moreover, Diclo (7.4 mg/kg and 14.8 mg/kg) and 
Ibu (60 mg/kg and 120 mg/kg) treatments reduced 
the relative weight of lymph node in dose dependent 
manner, and Para (36.7 mg/kg and 73.4 mg/kg) 
treated mice showed significant decrease relative           
to saline-treated mice. There were no significant 
differences in the relative and absolute weight of 
thymus in all treated mice when compared with 
saline-treated mice.  
 During the present study, the effects of Diclo, 
Ibu and Para on RBC and Plt in the Swiss albino 
mice are shown in figure 1. The results indicated 
that there is slight increase in RBCs count with 
Diclo (7.4 mg/kg), Ibu (60 mg/kg and 120 mg/kg) -
treated mice and a significant increase with admi-
nistration of Para (73.4 mg/kg), but no change in 
RBCs with Para (36.7 mg/kg) against control (Fig. 
1-A). In the term of Plt, Ibu (60 mg/kg), Para-treated 
(36.7 mg/kg and 73.4 mg/kg) mice did not differ 
significantly from the saline-treated group, however 
Diclo-inoculated (7.4 mg/kg and 14.8 mg/kg) mice 
had increased Plt count  and Ibu-treated (120 mg/kg) 
mice showed the highest significant value  compa-                                                                                     
ring to control mice (Fig. 1-B).  
 The results further revealed that significant 
increase in Hb content with high dose of Para              
and Ibu-injected mice as compared to saline-treated 
mice; while low dose of Diclo, Para, Ibu-treated 
mice indicated minor increase in Hb content. Also, 
there was slim decrease in Hb content of high dose 
of Diclo-inoculated mice (Fig. 2-A). Moreover, 
HCT percentage (Fig. 2-B) displayed a small eleva-
tion in Diclo (7.4 mg/kg); Ibu (60 mg/kg and 120 
mg/kg) and Para-treated (36.7 mg/kg and 73.4 
mg/kg) mice when compared to saline-treated group, 
even though Diclo-treated (14 mg/kg) mice presen-
ted minor decrease in HCT%. 
 
 
 
 
Figure 1. Effect of repeated administration of Diclo, Ibu or Para on RBCs and platelets count. Mice treated with saline 
(control), Diclo (7.4 mg/kg, 14.8 mg/kg), Ibu (60 mg/kg, 120 mg/kg), Para (36.7 mg/kg, 73.4 mg/kg) intraperitoneally (i.p.) 
daily for one month. Data were represented as mean ± SE (n = 3). *: Statistically significant comparison of control group 
and other treated groups (p < 0.05), **: Highly significant (p < 0.01).  
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Figure 2. Changes in HB concentration and HCT% after administration of Diclo, Ibu or Para. Mice treated with saline 
(control), Diclo (7.4 mg/kg, 14.8 mg/kg), Ibu (60 mg/kg, 120 mg/kg), Para (36.7 mg/kg, 73.4 mg/kg) intraperitoneally (i.p.) 
daily for one month. Data were represented as mean ± SE (n = 3). *: Statistically significant comparison of control group 
and other treated groups (p < 0.05), **: Highly significant (p < 0.01).  
 
 
 
Figure 3. Changes in IgG and IgM concentration in PB after repeated administration of different pain killers. Mice treated 
with saline (control), Diclo 1 (7.4 mg/kg), Diclo 2 (14.8 mg/kg), Para 1 (36.7 mg/kg), Para 2 (73.4 mg/kg), Ibu 1 (60 mg/kg), 
Ibu 2 (120 mg/kg) intraperitoneally (i.p.) daily for one month. Data were represented as mean ± SE (n = 3). *: Statistically 
significant comparison of control group and other treated groups (p < 0.05), **: Highly significant (p < 0.01).  
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 In figure 3-A, all treatments had reduced         
IgG concentration in dose dependent manner. Diclo 
treatment decreased IgG concentration from 42 to 38 
(mg/ml), Para treatment from 28 to 22 (mg/ml), and 
Ibu treatment from 51 to 36 (mg/ml) with increasing 
the dose of drug compared to control (41 mg/ml). 
The result more revealed that there was significant 
increase in IgM level with all treatments compared 
to saline treated mice (12 mg/ml). Increase in IgM 
levels was depend on the dose of drug, Diclo 
treatment increased IgM concentration from 28 to  
31 (mg/ml) and administration of Para augmented 
IgM level from 12.3 to 34 (mg/ml), however, Ibu 
treatment diminished the concentration from 52 to 
32.2 (mg/ml) (Fig. 3-B).  
 
 
 
Figure 4. Changes in C3 and C4 concentration in PB after repeated administration of different pain killers. Mice treated with 
saline (control), Diclo 1 (7.4 mg/kg), Diclo 2 (14.8 mg/kg), Para 1 (36.7 mg/kg), Para 2 (73.4 mg/kg), Ibu 1 (60 mg/kg), Ibu 2 
(120 mg/kg) intra-peritoneally (i.p.) daily for one month. Data were represented as mean ± SE (n = 3). *: Statistically 
significant comparison of control group and other treated groups (p < 0.05), **: Highly significant (p < 0.01).  
 
 
 
Figure 5. Changes in CRP concentration in PB after repeated administration of different pain killers. Mice treated with 
saline (control), Diclo 1 (7.4 mg/kg), Diclo 2 (14.8 mg/kg), Para 1 (36.7 mg/kg), Para 2 (73.4 mg/kg), Ibu 1 (60 mg/kg), 
Ibu 2 (120 mg/kg) intraperitoneally (i.p.) daily for one month. Data were represented as mean ± SE (n = 3). *: Statistically 
significant comparison of control group and other treated groups (p < 0.05), **: Highly significant (p < 0.01).  
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 In figure 4-A, Ibu (60 mg/kg and 120 mg/kg) 
and Para (36.7 mg/kg and 73.4 mg/kg) treatments 
had significantly reduced the concentration of 
complement component C3; while administration of 
Diclo revealed a non-significant decrease in comple-
ment C3 levels depending on the dose of Diclo when 
compared to control mice. Further, all examined 
treatments did not differ significantly from the 
control mice in terms of complement C4 (Fig. 4-B). 
Moreover, Ibu (60 mg/kg and 120 mg/kg) treatments 
slightly elevated CRP concentration in PB, while 
Diclo (7.4 mg/kg and 14.8 mg/kg) and Para-treated 
(36.7 mg/kg and 73.4 mg/kg) mice indicated signi-
ficant increase in comparison to saline-treated group 
(Fig. 5). 
 
4. DISCUSSION 
 
 NSAIDs are considered as a group of the  
most abused drugs by mains of combining the 
pharmacological actions of anti-inflammatory and 
analgesia, so they can easily be bought over the 
counter [38]. Alternative to NSAIDs, Para is 
recommended as a first-line treatment option for 
mild to moderate chronic pain [39] giving analgesia 
by raising the pain threshold, chiefly through a 
central rather than peripheral mechanism [40].  
Because NSAIDs and paracetamol are commonly 
used, we thought it is important to investigate their 
adverse effects on immunological and hematological 
parameters. 
 Alternations in the organ-body weight ratio 
may be a marker of cell constriction or inflammation 
and this constriction may occur as a result of lack          
of fluid from the organ related to damage, however 
an increase in organ-body weight ratio may refer          
to inflammation [41]. Further, numerous drugs are 
supposed to cause immunotoxic effects in humans 
and animals leading to disorders in the immune 
system that observed by alternations in immune 
related organs (spleen and thymus) weight [42]. 
Current results revealed all tested drugs caused non-
significant change in body weight, the relative and 
absolute weight of liver and kidney, however there 
were adverse effects on the relative and absolute 
weight of lymphoid organs (spleen, thymus and 
lymph nodes). Similar results were speculated by 
Oyedeji et al. [43] who reported that Para caused 
non-significant changes in the body weight of rats 
post treatment for 42 days and analysis of organ 
weight in toxicological studies is an important 
endpoint for recognition of potentially deleterious 
effects of chemicals [44] that may occur in the 
absence of any morphological changes [45].  
 The present study showed that Diclo admi-
nistration (14.8 mg/kg) caused decrease in RBCs 
count, Hb content and Hct%, despite there was no 
effect with Diclo at dose of 7.4 mg/kg concluding 
that it is dependent on dose toxicity. While Para and 
Ibu treatment showed increase in RBCs count, Hb 
content and Hct%. There was no change in platelets 
count with Para administration; however, Ibu and 
Diclo treatment presented elevation in their count. 
These results are in line with those of Thanagari et 
al. [46], El-Maddawy and El-Ashmawy [47] and 
Orinya et al. [48], who reported that Diclo induced 
highly significant decrease in Hb, PCV values 
resulting anemia that may refer to loss of blood 
during gastrointestinal bleeding that induced by 
diclofenac sodium. Moreover, chronic use of Ibu 
could affect hematological functions and time of 
exposure may promote ibuprofen toxicity depending 
on dose [49]. In addition, Para overdose causes liver 
damage based on the dose and this damage caused 
alterations in the red blood cell count, and packed 
cell volume [50, 51]. Para has the potential to inhibit 
erythropoietin release from the kidneys [52] 
resulting in the reduction in erythrocytes production, 
Hb concentration and Ht value and this may lead           
to anaemia. Further, the decrease in hematological 
parameters caused by Para may be attributed to the 
hyper-activity of bone marrow leading to the 
production of red blood cells with impaired integrity 
that are easily destroyed in the circulation [53].  
 NSAIDs have immunomodulatory effects by 
interfering with human T lymphocyte activation, 
proliferation and cytokine synthesis [54-56] through 
inhibition of Cox activity. Cox-2 is expressed in 
activated B lymphocytes that are required for opti-
mal antibody production predicting that NSAID 
therapy can have reverberations on antibody syn-
thesis [57, 58]. The current data revealed that by             
the end of treatment, there were significant down-
regulated activities of IgG in response to the 
examined drugs; however, IgM synthesis was 
enhanced with all tested drugs. In agreement with 
the present results, Bancos et al. [59] revealed that a 
panel of commonly used NSAIDs dulls antibody 
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synthesis in human peripheral blood mononuclear 
cells (PBMCs) and in purified B cells. Moreover, 
ibuprofen’s ability to diminish antibody production 
was dependent on concentration- and time and 
probably occurred via Cox-2 inhibition, as Cox-2           
is responsible for ibuprofen-mediated IgG, but not 
IgM inhibition. In addition, Diclo forms neoantigens 
with RBCs that may induce the production of 
autoantibodies and drug-dependent antibodies [60] 
leading to the production of antibodies against RBCs 
and/or platelets [61]. 
 Complement proteins are direct contributors 
in the maintenance of cellular turnover, healing, 
proliferation, regeneration and tissue integrity [62]. 
The results obtained herein revealed that Para or           
Ibu administration reduced levels of complement 
component C3 not C4 in serum, whereas Diclo 
treatment had a non-significant decrease in comple-
ment C3 levels in dose dependent manner and no 
effect on C4 level suggesting that the tested drugs 
activated the alternative complement pathway that 
relies on C3 not C4 leading to reduction of C3 level 
in serum. Our findings have been supported by 
Prohászka et al. [63] and Navratil et al. [64] who 
reported that hepatocytes changes or damage 
induced by paracetamol treatment is required for 
complement activation. In addition, complement 
components contribute in host tissue injury in 
several clinical conditions, and they are activated 
during hepatocytes regeneration for hepatoprotec-
tion through activation of C3 that is required for a 
normal hepatic regenerative response [65]. Further, 
the alternative complement pathway is activated, 
and may associate with deleterious reactions 
contributed to NSAID such as acute tubular injury 
induced by NSAID leading to acute kidney injury 
[66]. Moreover, some drugs like NSAIDs may 
directly stimulate effector mechanisms, such as the 
complement system by direct modulation of arachi-
donic acid pathway [67].  
 In the present study, a marked increase in 
CRP level was recorded in the sera of mice treated 
with Diclo, Ibu or Para for one month suggesting 
that continuous NSAIDs use may revert their effects 
on CRP levels in serum. These results were similar 
to those of Tarp et al. [68] who revealed the 
cyclooxygenase 2-selective NSAID lumiracoxib was 
associated with a significant increase in the CRP 
level and NSAIDs use for longer periods of time can 
lead to severe health problems like mucosal ulce-
ration and inflammation in the lower gastrointe-
stinal (GI) tract [69] that may be associated with 
elevation in CRP level [70]. Further, Para is 
recognized to have trifling anti-inflammatory effect 
and its overdose is linked with inflammation that 
marked by an increase in the inflammatory 
cytokines [71, 72]. 
  
5. CONCLUSION 
 
 From the present study, it is concluded that 
daily administration of Diclo, Ibu, or Para  for one 
month caused adverse effects on hematological 
parameters (RBCs, HB contents, HT% and Plts 
counts), and they caused immunomodulatory effects 
on levels of IgG and IgM, in addition to pertur-
bations in immune related organs (spleen, bone 
marrow and lymph node). These drugs also induced 
an increase in CRP level in serum and enhanced 
activation of alternative complement system that 
may contribute to deleterious reactions induced by 
tested drugs suggesting that continuous use of  
Diclo, Ibu, or Para may lead to development of 
haematotoxicity and immunotoxicity. So caution 
needs to be exercised in these drugs administration, 
which should be limited to the lowest therapeutic 
doses, to prevent its harmful effect. Further studies 
are needed to assess the relationships between 
administration of Diclo, Ibu or para and immuno-
logical and hematological perturbations.  
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